Sage Therapeutics, Inc.

SAGE · NASDAQ
Analyze with AI
6/30/2025
3/31/2025
12/31/2024
9/30/2024
Operating Activities
Net Income-$49,652-$62,214-$95,778-$93,551
Dep. & Amort.-$442-$981$129$255
Deferred Tax$0$0$0$0
Stock-Based Comp.$8,733$6,927$9,432$14,207
Change in WC$25,435-$25,435$20,758-$1,178
Other Non-Cash-$42,764-$25-$1,101-$2,098
Operating Cash Flow-$58,690-$81,728-$66,560-$82,365
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$68,602-$87,973-$88,704-$102,317
Inv. Sales/Matur.$149,620$133,756$135,278$183,371
Other Inv. Act.$0$0$0$0
Investing Cash Flow$81,018$45,783$46,574$81,054
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$1
Stock Repurch.$0$0$0$3
Dividends Paid$0$0$0$0
Other Fin. Act.-$65$148-$2$1,036
Financing Cash Flow-$65$148-$2$1,037
Forex Effect$0$0$0$0
Net Chg. in Cash$22,263-$35,797-$19,988$1,226
Supplemental Information
Beg. Cash$46,674$82,471$102,459$101,233
End Cash$68,937$46,674$82,471$102,459
Free Cash Flow-$58,690-$81,728-$66,560-$82,365
Sage Therapeutics, Inc. (SAGE) Financial Statements & Key Stats | AlphaPilot